Nevirapine (NVP) use to prevent maternal-infant HIV transmission: a randomized clinical trial of two doses of NVP compared to six weeks of NVP for the prevention of maternal-infant HIV transmission in the breastfeeding infant

Trial Profile

Nevirapine (NVP) use to prevent maternal-infant HIV transmission: a randomized clinical trial of two doses of NVP compared to six weeks of NVP for the prevention of maternal-infant HIV transmission in the breastfeeding infant

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2011

At a glance

  • Drugs Nevirapine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms SWEN
  • Most Recent Events

    • 11 Aug 2009 Actual end date (1 Apr 2007) added as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top